Pharmaceutical Regulatory Affairs: Drug Approval

Trace the evolution of U.S. drug laws from USP standards to FDA oversight, highlighting milestones such as 1906 Food and Drugs Act, 1938 FD&C Act, and 1962 Kefauver-Harris Amendment.

Regulatory affairs professionals guide drug development from research to market, ensuring CGMP, ICH, GCP, and GLP compliance while coordinating submissions to FDA, EMA, and DCGI.

Follow the FDA drug approval path from discovery through preclinical testing, IND submission, and phase 1 to phase 3 clinical trials to NDA review, labeling, GMP inspections, and post-marketing surveillance.

Explore the preclinical stage of new drug development, including computer simulations, lab and animal studies, prototype testing, multiple related compounds, safety assessments, GLP compliance, and groundwork for clinical trial design.

Explore how the investigational new drug application to the FDA authorizes human trials. Understand when an INDA is required, the IRB role, and how a clinical hold safeguards participants.

Navigate the new drug application (NDA) process, including CTD submission to the FDA's CDER, required sections, and steps from filing to potential approval or deficiencies.

Explore abbreviated new drug application (ANDA) process for generics, covering bioavailability and bioequivalence, CGMP, patent term basics, 180 days of exclusivity for the first to file, and the Hatch-Waxman framework.

Explore the four para-certifications under anda and their impact on timelines, including para-4's 180 days of exclusivity and the 20-day notice with a potential 30-month stay and four outcomes.

Exploring the ANDA process for generic drugs, this lecture details pharmaceutical equivalence, bioequivalence, and therapeutic equivalence criteria, and outlines CTD filing, FDA review, and pre-approval inspections.

Explore the categories of generic products, including ordinary generics, value-added generics, new delivery systems, biogenerics, branded generics, and patent-expired molecules, plus three entry pathways: line extensions, retargeting, and new products.

Innovator drugs, developed by the original company, are protected by about 20-year patents. Generics contain the same active ingredient and dosage form, are pharmaceutically and bioequivalent, therapeutically equivalent, and cheaper.

Compare NDA and ANDA, highlighting similarities in essential data and differences in testing scope. NDA requires bioavailability and clinical studies; ANDA relies on bioequivalence for generics, enabling faster approval.

Explore the Orange Book, the FDA's guide to approved drugs, and how it supports generic approvals by detailing bioequivalence, patents, and therapeutic equivalence classifications.

Explore how FDA therapeutic equivalence codes in the orange book guide interchangeability of multisource drugs, detailing A, AB, AN, BN, AO, AP, and AT classifications.

Understand how FDA B-codes identify equivalent but not therapeutically equivalent drugs, and how codes like B-star, BD, BE, BN, BR, BT, BEX, and BX signal data needs and formulation differences.

Explore how drug master files (DMFs) provide confidential manufacturing information to the FDA, support NDAs and ANDAs, and outline their types and regulatory review.

Explore DMF key terms, submission requirements, and FDA review stages for drug master files, including LOA, eCTD submissions via ESG, and annual updates.

Understand the DMF review workflow, including the FDA's retrieval of the DMF from the CDR, deficiency letters to the DMF holder, and potential delays to IND, NDA, or ANDA timelines.

Highlight key differences between regulatory applications (IND, NDA, ANDA) and DMFs: regulatory status, data management, submission to review division or CDR, and annual update reminders.

Explain the common technical document (CTD), a standardized format for drug registration dossiers across the US, EU, and Japan, harmonised by ICH and supporting five modules.

Compare ACTD and ICH-CTD structures, noting ACTD’s four-part format with integrated summaries and ASEAN focus, versus ICH-CTD’s five modules with module 2 and 3 quality data for global, innovative drugs.

Explore the electronic common technical document (ectd) and its five modules for regulatory submissions. Identify the advantages of streamlined submissions and improved navigation, and recognize costs and implementation challenges.

Compare paper CDD and electronic CDD (eCDD) across size, navigation, cross-references, submission, and storage, highlighting eCDD's efficiency, accessibility, and reduced packing compared with paper CTD.

Develop a tailored regulatory strategy for the preclinical phase, outlining data requirements and milestones to obtain regulatory approval and support lifecycle management.

Develop and implement regulatory strategy across clinical trial phases and post-approval, aligning phase i–iv design, maintaining regulatory compliance, timely revisions to submitted information, and ongoing submissions to support marketing authorization.

Explore how GMP safeguards quality, safety, and efficacy in pharmaceutical production by establishing a quality assurance framework with controlled conditions to prevent contamination, mislabeling, and incorrect ingredient levels.

Compare GMP and CGMP to understand their scope, cost, and application in pharmaceutical quality assurance. See that CGMP is current, technology-driven, and entails higher quality assurance and stricter process controls.

Learn the core principles of GMP compliance, including minimum standards, procedures, validation, contamination control, and designing quality into pharmaceutical manufacturing processes.

Survey the landscape of clinical research, from non-therapeutic and therapeutic studies to pharmacoeconomics, ethics committees and informed consent, and regulatory oversight across phase 1–4 trials.

Explore the BLA framework for biologics and the Purple Book database, detailing reference products, biosimilars, exclusivity periods, and guidance for substitution and regulatory compliance.